^
    Apply
    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (KEYNOTE-F62) (NCT06108050)
    Phase 1
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    11/07/2023
    Primary completion :
    11/30/2027
    Completion :
    05/31/2028
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • JZP898
    Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (INFINITE) (NCT03710876)
    Phase 3
    Ferring Ventures Limited
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/21/2019
    Primary completion :
    03/29/2024
    Completion :
    04/01/2026
    MSLN • EFEMP1
    |
    gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral
    A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (NCT04157517)
    Phase 1/2
    Takeda
    Completed
    Last update posted :
    12/14/2023
    Initiation :
    12/12/2019
    Primary completion :
    11/04/2023
    Completion :
    11/04/2023
    BRAF • CTLA4
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • modakafusp alfa (TAK-573)
    CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma (NCT00574730)
    Phase N/A
    University of Nebraska
    Completed
    Last update posted :
    09/14/2023
    Initiation :
    05/23/2001
    Primary completion :
    08/01/2005
    Completion :
    06/07/2012
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ViraferonPeg (peginterferon-α-2b)
    Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression (IPOS) (NCT04798612)
    Phase 2
    Zealand University Hospital
    Recruiting
    Last update posted :
    08/17/2023
    Initiation :
    08/14/2023
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    CD8 • CD4
    |
    Pegasys (pegylated interferon α -2a)
    A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT (TEM-GBM) (NCT03866109)
    Phase 1/2
    Genenta Science
    Recruiting
    Last update posted :
    01/20/2023
    Initiation :
    03/05/2019
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    MGMT
    |
    Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
    A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 (NCT00000754)
    Phase 2
    National Institute of Allergy and Infectious Di...
    Completed
    Last update posted :
    11/04/2021
    Completion :
    02/01/1995
    CD4
    |
    Roferon A (recombinant interferon alfa-2a)
    Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection. (NCT00000764)
    Phase 1
    National Institute of Allergy and Infectious Di...
    Completed
    Last update posted :
    10/28/2021
    Completion :
    07/01/1996
    CD4
    |
    Roferon A (recombinant interferon alfa-2a)
    Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia (NCT02328755)
    Phase 1/2
    University of Michigan Rogel Cancer Center
    Completed
    Last update posted :
    10/06/2021
    Initiation :
    01/01/2015
    Primary completion :
    03/25/2019
    Completion :
    03/25/2019
    IFNA1
    |
    Pegasys (pegylated interferon α -2a)
    Malaysia Stop Tyrosine Kinase Inhibitor Trial (MSIT) (NCT02381379)
    Phase 3
    Ministry of Health, Malaysia
    Unknown status
    Last update posted :
    09/14/2020
    Initiation :
    03/01/2015
    Primary completion :
    10/01/2018
    Completion :
    10/01/2021
    ABL1 • BCR
    |
    Pegasys (pegylated interferon α -2a)
    STI571 ProspectIve RandomIzed Trial: SPIRIT (NCT00219739)
    Phase 3
    Poitiers University Hospital
    Completed
    Last update posted :
    04/13/2020
    Initiation :
    09/01/2003
    Primary completion :
    12/01/2014
    Completion :
    12/01/2014
    ABL1 • BCR
    |
    imatinib • cytarabine • Roferon A (recombinant interferon alfa-2a)
    Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) (NCT01259856)
    Phase 3
    Ronald Hoffman
    Completed
    Last update posted :
    04/30/2019
    Initiation :
    09/01/2011
    Primary completion :
    06/30/2017
    Completion :
    06/30/2017
    JAK2
    |
    JAK2 V617F
    |
    Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin
    Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755) (NCT01544920)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    09/11/2018
    Initiation :
    05/30/2012
    Primary completion :
    05/19/2015
    Completion :
    05/19/2015
    IFNL3
    |
    Pegasys (pegylated interferon α -2a) • ViraferonPeg (peginterferon-α-2b)
    Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults (NCT00678951)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    11/06/2017
    Initiation :
    05/01/2008
    Primary completion :
    01/01/2016
    Completion :
    01/01/2016
    NF1
    |
    Zarnestra (tipifarnib) • ViraferonPeg (peginterferon-α-2b)
    Study of PEG-Intron for Plexiform Neurofibromas (NCT00396019)
    Phase 2
    University of Pittsburgh
    Completed
    Last update posted :
    11/06/2017
    Initiation :
    12/01/2006
    Primary completion :
    04/01/2014
    Completion :
    04/01/2014
    NF1
    |
    ViraferonPeg (peginterferon-α-2b)
    Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (NCT01687244)
    Phase 2
    FKD Therapies Oy
    Completed
    Last update posted :
    07/24/2017
    Initiation :
    09/01/2012
    Primary completion :
    10/01/2015
    Completion :
    01/01/2016
    IFNA1
    |
    IFNA2 elevation
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (NCT01496807)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    04/28/2017
    Initiation :
    02/17/2012
    Primary completion :
    03/16/2016
    Completion :
    08/29/2016
    BRAF
    |
    Yervoy (ipilimumab) • ViraferonPeg (peginterferon-α-2b)
    Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) (NCT00759109)
    Phase 3
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    04/07/2017
    Initiation :
    03/01/2002
    Primary completion :
    11/01/2009
    Completion :
    11/01/2009
    AFP • PCNA
    |
    ViraferonPeg (peginterferon-α-2b)
    Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation (NCT01463956)
    Phase 2
    French National Agency for Research on AIDS and...
    Completed
    Last update posted :
    01/24/2017
    Initiation :
    01/06/2012
    Primary completion :
    06/01/2014
    Completion :
    01/22/2015
    IFNL3 • ITPA
    |
    ViraferonPeg (peginterferon-α-2b)
    Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (NCT01259817)
    Phase 2
    Ronald Hoffman
    Completed
    Last update posted :
    01/11/2017
    Initiation :
    09/01/2011
    Primary completion :
    12/01/2016
    Completion :
    12/01/2016
    JAK2 • CALR
    |
    JAK2 V617F
    |
    Pegasys (pegylated interferon α -2a) • hydroxyurea • aspirin
    HCV Treatment in HIV Co-Infected Patients in Asia (NCT01838772)
    Phase 4
    amfAR, The Foundation for AIDS Research
    Completed
    Last update posted :
    10/27/2016
    Initiation :
    12/01/2013
    Primary completion :
    06/01/2016
    Completion :
    09/01/2016
    AFP • CD4
    |
    ViraferonPeg (peginterferon-α-2b)
    Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) (NCT02736721)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    09/20/2016
    Initiation :
    09/01/2003
    Primary completion :
    11/01/2010
    Completion :
    11/01/2010
    ABL1 • BCR
    |
    Pegasys (pegylated interferon α -2a)
    High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (NCT00050531)
    Phase 3
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/11/2016
    Initiation :
    04/01/2003
    Primary completion :
    04/01/2007
    Completion :
    08/01/2015
    IFNA1
    |
    imatinib • Leukine (sargramostim) • ViraferonPeg (peginterferon-α-2b)
    Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (PITCH) (NCT01637532)
    Phase 1/2
    Leiden University Medical Center
    Completed
    Last update posted :
    01/26/2016
    Initiation :
    02/01/2011
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    MUC16
    |
    MUC16 elevation
    |
    carboplatin • pegylated liposomal doxorubicin • Actemra IV (tocilizumab) • ViraferonPeg (peginterferon-α-2b) • doxorubicin liposomal
    A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (NCT00536588)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    03/27/2015
    Initiation :
    09/01/2006
    Primary completion :
    08/01/2009
    Completion :
    08/01/2009
    IFNA1
    |
    Adstiladrin (nadofaragene firadenovec-vncg)